Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Ovarian Neoplasms 33Breast Neoplasms 26Triple Negative Breast Neoplasms 17Prostatic Neoplasms 16Fallopian Tube Neoplasms 11Neoplasms 9Fanconi Anemia, Complementation Group D1 7Endometrial Neoplasms 7Pancreatic Neoplasms 6Glioma 6Carcinoma, Ovarian Epithelial 6Stomach Neoplasms 5Small Cell Lung Carcinoma 5Sarcoma 5Neoplasm Metastasis 5Cholangiocarcinoma 5Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Lymphoma, Non-Hodgkin 4Carcinoma, Non-Small-Cell Lung 4Advanced Breast Cancer 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Osteosarcoma 3Lung Neoplasms 3Glioblastoma 3Colorectal Neoplasms 3Carcinosarcoma 3Carcinoma, Renal Cell 3Wilms Tumor 2

Interventions

apatinib 3vistusertib 2olaparib 2camrelizumab 2atezolizumab 2Ipilimumab 2Everolimus 2trametinib 1toripalimab 1tilsotolimod 1tazemetostat 1tazarotene 1spartalizumab 1seviteronel 1sargramostim 1sacituzumab govitecan 1rucaparib 1roniciclib 1romiplostim 1pyrotinib 1phosphorylethanolamine 1pemigatinib 1pembrolizumab 1pazopanib 1palbociclib 1niraparib 1magrolimab 1lenvatinib 1irinotecan sucrosofate 1famitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Solid Tumor × olaparib × Clear all
NCT05522491 2025-12-11

Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer

Hebei Medical University Fourth Hospital

Phase 2 Not yet recruiting
30 enrolled
Other solid neoplasm

Solid Tumor

NCT06739395 2024-12-18

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

Tianjin Medical University Second Hospital

Phase 2 Recruiting
300 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡